Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial

Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial

The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EBioMedicine 2021-08, Vol.70, p.103511-103511, Article 103511
Hauptverfasser: Awoyemi, Ayodeji, Mayerhofer, Cristiane, Felix, Alex S., Hov, Johannes R., Moscavitch, Samuel D., Lappegård, Knut Tore, Hovland, Anders, Halvorsen, Sigrun, Halvorsen, Bente, Gregersen, Ida, Svardal, Asbjørn, Berge, Rolf K., Hansen, Simen H., Götz, Alexandra, Holm, Kristian, Aukrust, Pål, Åkra, Sissel, Seljeflot, Ingebjørg, Solheim, Svein, Lorenzo, Andrea, Gullestad, Lars, Trøseid, Marius, Broch, Kaspar
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Anti-Bacterial Agents - therapeutic use
Antibiotics
Basale medisinske, odontologiske og veterinærmedisinske fag: 710
Basic medical, dental and veterinary science disciplines: 710
Cardiac Output
Exercise Test
Female
Gastrointestinal Microbiome
General & Internal Medicine
Heart failure
Heart Failure - drug therapy
Heart Failure - microbiology
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Inflammation
Life Sciences & Biomedicine
Male
Medical disciplines: 700
Medicine, General & Internal
Medicine, Research & Experimental
Medisinske Fag: 700
Microbiota
Middle Aged
Probiotics
Probiotics - therapeutic use
Research & Experimental Medicine
Research Paper
Rifaximin - therapeutic use
Saccharomyces boulardii - pathogenicity
Science & Technology
Standard of Care
Trimethylamine N-oxide
VDP
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF). In a multicentre, prospective randomized open label, blinded end-point trial, we randomized patients with LVEF
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2021.103511